Chapter 6: Optimizing Study Closeout in CDM and PV

Author

Miss Devi Sravanthi Yamala,

PharmD Scholar, Department of Pharmacy Practice, Sir C.R.Reddy College of Pharmaceutical Sciences, Eluru, Andhra Pradesh, India

Abstract

The conclusion of a clinical trial is defined by the high-stakes and irreversible process of Database Lock, the definitive milestone where the study dataset is deemed final, immutable, and ready for statistical analysis. Reaching this point requires the convergence of all data cleaning activities into a state of verifiable integrity. A critical prerequisite for lock is Serious Adverse Event (SAE) Reconciliation, a mandatory quality assurance process that ensures the clinical database (EDC) and the safety database (e.g., Argus) contain identical information regarding patient safety outcomes. Discrepancies between these two sources, whether in dates or medical terminology, must be investigated and resolved to prevent conflicting data in the final regulatory submission. The closeout phase also involves rigorous Quality Control (QC) and Quality Assurance (QA) audits to verify that the Data Management Plan was strictly followed and that the error rate in critical variables is within acceptable tolerance limits. Once the data is declared clean, the database typically moves through a "Freeze" state for final review before the "Hard Lock" is executed, triggering the unblinding of treatment codes. The lifecycle concludes with the secure Archiving of the study data in long-term, read-only formats like PDF/A and SAS XPORT, and the transformation of the dataset into CDISC standards (SDTM and ADaM) for electronic transfer to regulatory authorities, ensuring that the evidence of the trial is preserved and accessible for decades of future inspection.

Keywords: Database Lock, SAE Reconciliation, Quality Control (QC), Data Archiving, CDISC Standards (SDTM/ADaM)

VIEW PDF